Amplia Therapeutics Limited (ASX:ATX)

Market Cap	125.70M +337.9%
Revenue (ttm)	5.01M +46.8%
Net Income	-7.93M
EPS	-0.02
Shares Out	513.07M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,816,190
Average Volume	6,925,429
Open	0.2200
Previous Close	0.2300
Day's Range	0.2200 - 0.2670
52-Week Range	0.0490 - 0.4250
Beta	0.77
RSI	68.37
Earnings Date	May 29, 2026

About Amplia Therapeutics

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ATX

Financial Performance

In fiscal year 2025, Amplia Therapeutics's revenue was 3.78 million, a decrease of -15.03% compared to the previous year's 4.45 million. Losses were -6.57 million, 45.9% more than in 2024.